8:00am - 8:20am

Personalized Cancer Vaccines for Melanoma

Catherine Wu

8:20am - 8:35am

ACTengine IMA203 TCR-T targeting PRAME in PD1 refractory metastatic melanoma

Martin Wermke

8:35am - 8:55am

L-fucose: a dietary sugar to therapeutically alter tumor:immune interactions

Eric Lau

8:55am - 9:10am

NK cells can drive resistance to anti-PD1-based therapy in T-cell excluded melanoma

Joanna Pozniak

9:10am - 9:25am

Preliminary safety and efficacy from an open-label, multicenter, phase 1 study of RP2 as a single agent and in combination with nivolumab in a cohort of patients with uveal melanoma

Joseph Sacco

9:25am - 9:45am

Checkpoints, Cell Therapies, and Emerging Data

Sapna Patel

9:45am - 10:00am

Stratified analysis of checkpoint blockade regimens in metastatic melanoma leads to rational discovery of hypoxia-related targets in immune high tumors

 Amy Huang 

10:45am - 11:05am

20 Mins

Phenotype-switching in melanoma

Colin Goding

11:05am - 11:20am

15 Mins

Defining subpopulations of melanocytes in human skin

Bishal Tandukar

11:20am - 11:40am

20 Mins

Dissecting the magnitude and origin of melanoma plasticity and phenotypic diversity

Christophe Marine

11:40am - 11:55am

15 Mins

Melanocyte progenitor subpopulations in response to UV radiation and in vitiligo

Mark Shackleton

11:55am - 12:10pm

15 Mins

Characterizing how the skin microenvironment restrains melanoma progression

Yilun Ma

12:10pm - 12:30pm

20 Mins

Phenotype diversity and instability in healthy and transformed melanocytes

Robert Judson-Torres

10:45am - 11:05am

20 Mins

Invited Presentation 

Boris Bastian

11:05am - 11:20am

15 Mins

Functional roles of enhancers in immune microenvironment and immunotherapy response

Kunal Rai

11:20am - 11:35am

15 Mins

CDS2 is an essential gene in uveal melanoma

Jenny Pui Ying Chan

11:35am - 11:50am

15 Mins

MacroH2A restricts inflammatory gene expression in melanoma cancer-associated fibroblasts by coordinating chromatin looping

Dan Filipescu

11:50am - 12:05pm

15 Mins

Investigation of the sexual dimorphic tumor suppressor role of DDX3X in melanoma

Marine Lingrand

12:05pm - 12:25pm

20 Mins

The generation of cancer specific ribosomes suppresses anti tumour immunity

Elenora Leucci

2:00pm - 3:15pm

75 Mins

Increasing DEI in melanoma research: from bench to beside to community

Donita Brady, Gabriela Cinat and Susan Swetter

3:45pm - 4:05pm

20 Mins

Metabolic regulation of melanoma tumor immunity

Bin Zheng

4:05pm - 4:20pm

15 Mins

HDAC8 promotes melanoma immune escape by increasing MDSC accumulation and decreasing T-cell recognition

Michael Emmons

4:20pm - 4:35pm

15 Mins

Electrical activity driven regulation of the melanoma microenvironment

Mohita Tagore

4:35pm -4:55pm

20 Mins

Lymph-borne, melanoma-derived proteins condition the lymph node for metastasis

Amanda Lund

4:55pm - 5:10pm

15Mins

Transglutaminase-2 expression is elevated in the invasive melanoma cell state and modulates the tumor immune microenvironment

Signe Caksa

5:10pm - 5:25pm

15 Mins

Tumor-Immune Profiling of Metastatic Melanoma Patients Reveals Biomarkers of Response to Combination Anti-LAG-3 + Anti-PD-1-based Immunotherapies

Tuba Gide

5:25pm - 5:45pm

20 Mins

Invited Presentation 

Marisol Soengas

3:45pm - 4:05pm

20 Mins

Primary Melanoma DNA and Methylation Classes and Survival in the InterMEL Study

Nancy Thomas

4:05pm - 4:20pm

15 Mins

Functional characterization of non-coding CDKN2B variants found in high-risk melanoma families

Abigail Dennis

4:20pm - 4:40pm

20 Mins

Melanoma and CDKN2A: what have we learned in 30 years? 

Alisa Goldstein

4:40pm - 4:55pm

15 Mins

Correlation of Family History of Auto-Immune disease and Immune Related Adverse Events: A Retrospective Study

Marcus Dempster

4:55pm - 5:15pm

20 Mins

Invited Presentation 

Paolo Dotto

5:15pm - 5:35pm

20 Mins

The Interplay of host, microbial, and tumor metabolism: Obesity, diet, and immunotherapy responsse

Jennifer McQuade